Time to care
Securing a future for the hospital workforce in Europe
In light of rising demand, staff shortages and lack of time for hands-on-care, is the current hospital workforce model sustainable? New research released by the Deloitte UK Centre for Health Solutions explores the current state of hospital workforces across Europe and their key challenges.
The future awakens
Life Sciences and Health Care Predictions 2022
The year is 2022. The quantified self is alive and well, digital technologies have transformed the culture of health care and new entrants have disrupted delivery models. These are some of our predictions that, if they come true, will shake up the life sciences and health care industry.
The digital hospital of the future
In 10 years, technology may change the face of global health care delivery
Learn how the digital hospital of the future can leverage technology to transform the future of health care delivery, including digital patient experience in this report developed by Deloitte US.
Under the spotlight
Data integrity in life sciences
Regulatory bodies now have high expectations with regard to data quality and integrity owing to the life sciences industry’s growth, globalization and adoption of advanced technology, such as highly automated systems and storage of data in ‘The Cloud’. Read the report to learn more.
High-value health care
Innovative approaches to global challenges
What are pioneering health care providers, health plans, and life science companies doing to anticipate patient needs, reduce costs, and improve overall health outcomes in the US and globally? Learn more in this new Deloitte Center for Health Solutions research.
Identification of Medicinal Products
Identification of Medicinal Products (IDMP) is one the biggest regulatory challenges for all pharmaceutical companies operating in Europe. How can your organisation navigate this journey towards increased patient safety and use it as an opportunity for business transformation?
Facing the tidal wave
De-risking pharma and creating value for patients
The pharmaceutical industry is facing a ‘tidal wave’ of complex age and behaviour-related diseases creating increased economic, scientific and delivery risks. How can pharma companies evolve to overcome these obstacles?